Characteristics of the 54 cases of B-cell non-Hodgkin's lymphoma (NHL) and Hodgkin’s lymphoma
| Histology | |
| DLBCL | 27 (50.0) |
| Follicular | 8 (14.8) |
| Marginal zone | 8 (14.8) |
| Hodgkin lymphoma | 3 (5.6) |
| Mantle cell | 3 (5.6) |
| NHL (not specified) | 3 (5.6) |
| Lymphocytic | 1 (1.8) |
| MALT | 1 (1.8) |
| EBV positivity on immunochemistry* | 4 (14.8) |
| Ann Arbor staging† | |
| I | 19 (35.2) |
| II | 7 (13.0) |
| III | 6 (11.1) |
| IV | 19 (35.2) |
| Malignant transformation from indolent lymphoma | 4 (7.4) |
| Localisation | |
| Lymphatic nodes | 32 (59.3) |
| Solid organs | 12 (22.2) |
| Bone marrow | 11 (20.4) |
| Blood | 3 (5.6) |
| Salivary gland | 3 (5.6) |
| Skin | 3 (5.6) |
| Bone | 2 (3.7) |
| ENT | 2 (3.7) |
| Spleen | 2 (3.7) |
| Lymphoma-specific treatment | 50 (92.6) |
| Chemotherapy | 36 (66.7) |
| Rituximab only | 11 (20.4) |
| Radiotherapy | 7 (13.0) |
| Surgery | 4 (7.4) |
| Therapeutic abstention | 4 (7.4) |
| Remission after 1st line | 32 (59.3) |
| Remission after 2nd line | 7 (13.0) |
| Remission after 3rd line | 0 (0.0) |
| Deaths | 14 (25.9) |
| Lymphoma-related | 11 (20.4) |
| Non lymphoma-related | 3 (5.6) |
| Follow-up duration after lymphoma onset, years, mean (SD) | 5.2 (5.8) |
Data are n (%) unless otherwise indicated.
Of note, EBV-positive lymphomas were DLBCL (2/4) and Hodgkin’s lymphoma (2/4).
*Total number of patients tested for EBV: 27
†Total number of patients with available data for Ann Arbor staging: 51
DLBCL, diffuse large B-cell lymphoma; EBV, Epstein-Barr virus; ENT, ear nose throat; MALT, mucosa-associated lymphoid tissue